secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-047143
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q3 revenue up 30% to $30.6M; raises Cell Processing guidance to $72-73M
--------------------------------------------------------------------------------

- Q3 revenue $30.6M (+30% YoY); Cell Processing $19.0M (+43% YoY); adjusted EBITDA $6.1M (20% margin).
- GAAP net loss from continuing ops $1.7M vs $15.8M YoY; adj. gross margin 54% (up from 44%).
- Completed sale of SciSafe biostorage business for $73M cash on Nov 12, 2024.
- FY2024 revenue guidance revised to $98-100M; Cell Processing raised to $72-73M (previously $70-71M).
- Biostorage guidance cut to $26-27M due to SciSafe divestiture; management expects positive adjusted EBITDA for full year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828024047143/0001628280-24-047143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828024047143/blfs-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer